Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.

Zogenix, Inc.

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Corbus Pharmaceuticals Holdings, Inc.

UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases that have significant unmet needs. This includes discovery, development, and delivery of therapies with a culture of care around patient value.

Metric
Company Name	Zogenix, Inc.	Corbus Pharmaceuticals Holdings, Inc.
Symbol	ZGNX	CRBP
MSH ID	COM:ZOGENIX	COM:CORBUSPHARMA
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology
Country	US	US
Stage		Post-IPO Equity
Employee Count	327	19
Website	zogenix.com	corbuspharma.com
LinkedIn
Founders

Metric
Market Cap		550.26M
Enterprise Value
Monthly Web Traffic		4.09K
Web Traffic Growth		-0.53
Valuation
Raised Capital		94.50M

Metric
Revenue	81.69M
Revenue (LTM)
Revenue (NTM)
Gross Profit	76.86M
EBITDA	-202.58M
Operating Income	-212.03M
Net Income	-227.41M
EPS	-4.24
Diluted EPS	-4.24
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.94
Operating Profit Margin	-2.60
EBITDA Margin	-2.48
Net Profit Margin	-2.78
Return on Equity	-0.83
Return on Assets	-0.49
Return on Capital Employed	-0.57

COM:ZOGENIX

UCB

Last Close

26.68

01/01 00:00

Volume Today

11.25M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-6.30
P/B Ratio	8.00
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple	0.33

Metric
Days Sales Outstanding	45.30
Days Payables Outstanding	1.66K
Days Inventory Outstanding	414.68
Operating Cycle	459.99
Cash Conversion Cycle	-1.20K
Asset Turnover	0.17

Metric
Operating Cash Flow	-185.31M
Free Cash Flow	-185.39M
Cash Flow to Debt	-1.10
Operating Cash Flow/Sales	-2.27
Free Cash Flow Yield

Metric
Cash & Equivalents	101.18M
Accounts Receivable	-6.32M
Inventory	5.49M
Goodwill	6.23M
Debt to Capitalization	0.48
Debt to Assets	0.62
Current Ratio	3.63
Quick Ratio	3.19

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.43
R&D to Revenue	1.75
SG&A to Revenue